Search Results - "Journal of viral hepatitis"

Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis by Platt, Lucy, French, Clare E., McGowan, Catherine R., Sabin, Keith, Gower, Erin, Trickey, Adam, McDonald, Bethan, Ong, Jason, Stone, Jack, Easterbrook, Philippa, Vickerman, Peter

“…Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV‐HBsAg…”
Get full text

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm by Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balık, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales Jr, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., Øvrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B., Estes, C.

“…Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the…”
Get full text

Gut microbiota dysbiosis in patients with hepatitis B virus–induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma by Zeng, Yongbin, Chen, Shanjian, Fu, Ya, Wu, Wennan, Chen, Tianbin, Chen, Jing, Yang, Bin, Ou, Qishui

“…The information regarding the effect of hepatitis B virus (HBV) infection on gut microbiota and the relationship between gut microbiota dysbiosis and hepatitis…”
Get full text

National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care by El‐Akel, W., El‐Sayed, M. H., El Kassas, M., El‐Serafy, M., Khairy, M., Elsaeed, K., Kabil, K., Hassany, M., Shawky, A., Yosry, A., Shaker, M. K., ElShazly, Y., Waked, I., Esmat, G., Doss, W.

“…Summary Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated…”
Get full text

Historical epidemiology of hepatitis C virus (HCV) in selected countries by Bruggmann, P., Berg, T., Øvrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balık, İ., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales Jr, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., Hindman, S. J.

“…Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a…”
Get full text

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension by Afdhal, N., Everson, G. T., Calleja, J. L., McCaughan, G. W., Bosch, J., Brainard, D. M., McHutchison, J. G., De‐Oertel, S., An, D., Charlton, M., Reddy, K. R., Asselah, T., Gane, E., Curry, M. P., Forns, X.

“…Summary Portal hypertension is a predictor of liver‐related clinical events and mortality in patients with hepatitis C and cirrhosis. The effect of…”
Get full text

Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis by Friedrich-Rust, M., Nierhoff, J., Lupsor, M., Sporea, I., Fierbinteanu-Braticevici, C., Strobel, D., Takahashi, H., Yoneda, M., Suda, T., Zeuzem, S., Herrmann, E.

“…  Acoustic Radiation Force Impulse (ARFI) imaging is a novel ultrasound‐based elastography method that is integrated in a conventional ultrasound machine…”
Get full text

Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy by Knop, V., Hoppe, D., Welzel, T., Vermehren, J., Herrmann, E., Vermehren, A., Friedrich-Rust, M., Sarrazin, C., Zeuzem, S., Welker, M.-W.

“…Summary It is still controversial, whether and to what amount cirrhosis and portal hypertension are reversible in patients with hepatitis C virus…”
Get full text

Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy by Rodríguez‐Tajes, Sergio, Miralpeix, Anna, Costa, Josep, López‐Suñé, Ester, Laguno, Montserrat, Pocurull, Anna, Lens, Sabela, Mariño, Zoe, Forns, Xavier

“…A significant proportion of patients infected with SARS‐CoV‐2 develop severe respiratory symptoms due to an excessive immune response. Treatment of this…”
Get full text

Roadmap to functional cure of chronic hepatitis B: An expert consensus by Ning, Qin, Wu, Di, Wang, Gui-Qiang, Ren, Hong, Gao, Zhi-Liang, Hu, Peng, Han, Mei-Fang, Wang, Yan, Zhang, Wen-Hong, Lu, Feng-Min, Wang, Fu‐Sheng

“…Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide. HBsAg loss is associated with functional remission and improved…”
Get full text

Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infection by Chen, Liping, Huang, Shaoping, Yang, Jingmao, Cheng, Xin, Shang, Zhiyin, Lu, Hongzhou, Cheng, Jilin

“…COVID‐19 has become a global pandemic and garnered international attention. Although the clinical features of COVID‐19‐related liver injury have been…”
Get full text

Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis by Campbell, Cori, Wang, Tingyan, McNaughton, Anna L., Barnes, Eleanor, Matthews, Philippa C.

“…Hepatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide and is a leading cause of death in individuals with chronic…”
Get full text

Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey by Kim, Hyun‐seok, Yang, Ju Dong, El‐Serag, Hashem B., Kanwal, Fasiha

“…Summary The World Health Organization has set the goal of reducing the hepatitis‐related mortality rate by 65% between 2015 and 2030. Diagnosis and awareness…”
Get full text

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial by Omata, Masao, Nishiguchi, Shuhei, Ueno, Yoshiyuki, Mochizuki, Hitoshi, Izumi, Namiki, Ikeda, Fusao, Toyoda, Hidenori, Yokosuka, Osamu, Nirei, Kazushige, Genda, Takuya, Umemura, Takeji, Takehara, Tetsuo, Sakamoto, Naoya, Nishigaki, Yoichi, Nakane, Kunio, Toda, Nobuo, Ide, Tatsuya, Yanase, Mikio, Hino, Keisuke, Gao, Bing, Garrison, Kimberly L., Dvory-Sobol, Hadas, Ishizaki, Akinobu, Omote, Masa, Brainard, Diana, Knox, Steven, Symonds, William T., McHutchison, John G., Yatsuhashi, Hiroshi, Mizokami, Masashi

“…Summary Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV –…”
Get full text

Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection by Gupta, S., Rout, G., Patel, A. H., Mahanta, M., Kalra, N., Sahu, P., Sethia, R., Agarwal, A., Ranjan, G., Kedia, S., Acharya, S. K., Nayak, B., Shalimar

“…Summary Novel direct‐acting antivirals (DAAs) are now the standard of care for the management of hepatitis C virus (HCV) infection. Branded DAAs are associated…”
Get full text

Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta by Wranke, Anika, Hardtke, Svenja, Heidrich, Benjamin, Dalekos, George, Yalçin, Kendal, Tabak, Fehmi, Gürel, Selim, Çakaloğlu, Yilmaz, Akarca, Ulus S, Lammert, Frank, Häussinger, Dieter, Müller, Tobias, Wöbse, Michael, Manns, Michael P., Idilman, Ramazan, Cornberg, Markus, Wedemeyer, Heiner, Yurdaydin, Cihan

“…Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG‐interferon alpha‐2a (PEG‐IFNα‐2a) is the only effective treatment but…”
Get full text

Strategies to manage hepatitis C virus (HCV) disease burden by Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balık, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales Jr, F. L., Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., Øvrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., Gower, E.

“…Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was…”
Get full text

Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers by Zou, H., Chen, Y., Duan, Z., Zhang, H., Pan, C.

“…In infants born to hepatitis B surface antigen (HBsAg)–positive mothers, failure after passive–active immunization still occurs. The role of maternal hepatitis…”
Get full text

Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study by Shiha, Gamal, Mousa, Nasser, Soliman, Reham, NNH Mikhail, Nabiel, Adel Elbasiony, Mohamed, Khattab, Mahmoud

“…Liver cirrhosis is an important risk factor for hepatocellular carcinoma. The reported annual incidence of HCC is about 3%‐8% in CHC cirrhotic patients. Based…”
Get full text

COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later by Ekpanyapong, Sirina, Bunchorntavakul, Chalermrat, Reddy, K. Rajender

“…Globally, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 virus) has been a major cause for significant morbidity and mortality. Since the…”
Get full text